ASCO 2016 highlights for immunotherapy

Hendrik-Tobias Arkenau, MD, PhD from the Sarah Cannon Research Institute, London, UK discusses his highlights from the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Dr Arkenau points out that immunotherapy used to treat various cancers such as melanoma, renal cell, and lung cancer, is a key topic. Dr Arkenau discusses the use of a PD-L1 inhibitor called avelumab in patients with gastric cancers. Furthermore, Dr Arkenau talks about advancements in patients with mismatch repair gene defects, which, for example, occur in around 5% of colon cancer patients.

Share this video